Advertisement
Screener

REGEN BIOPHARMA, INC. (RGBP) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

1.4 / 5 stars · 23/80 Roast Me

REGEN BIOPHARMA, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

REGEN BIOPHARMA, INC. (RGBP) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 726.00% for the 12-month period ending 2020-09-30, per its 10-K filed 2021-08-04.

Discontinued › Notes › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2021-08-05

  • REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2019-12-31 was 288.00%, a 1.58% increase year-over-year.
  • REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2018-12-31 was 283.52%, a 51.61% increase year-over-year.
  • REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for the quarter ending 2017-12-31 was 187.00%.
  • REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2020 was 726.00%, a 165.74% increase from fiscal 2019.
  • REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2019 was 273.20%, a 13.10% decline from fiscal 2018.
  • REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2018 was 314.37%, a 80.67% increase from fiscal 2017.
  • REGEN BIOPHARMA, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2017 was 174.00%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum 12 month
2020-09-30726.00%
10-K · filed 2021-08-04
2020-06-30312.00%
10-Q · filed 2021-08-05
2020-03-31312.00%
10-Q · filed 2021-08-05
2019-12-31288.00%
10-Q · filed 2021-08-05
2019-09-30273.20%
10-K · filed 2021-06-21
2019-06-30273.20%
10-Q · filed 2019-10-24
2019-03-31273.20%
10-Q · filed 2019-08-29
2018-12-31283.52%
10-Q · filed 2019-02-12
2018-09-30314.37%
10-K · filed 2018-12-27
2017-12-31187.00%
10-Q · filed 2018-02-06
2017-09-30174.00%
10-K · filed 2018-01-05